Sensitization and allergic response and intervention therapy in animal models.

A review is presented of 3 murine models and a swine neonatal model used to investigate immunotherapeutic options. In Model 1, mutation of linear IgE-binding epitopes of Ara h 1 for the preparation of a hypoallergenic Ara h 1 is discussed with respect to expression in transgenic tobacco plants and correct folding following expression in the pET16b construct. In Model 2, the mutations of Ara h 1 were assessed for use as an immunotherapeutic agent. Although some protective benefit was observed with the modified Ara h 1 protein, animals desensitized with heat-killed E. coil preparations showed increased protection to challenge. In Model 3, soybean homologs to peanut proteins were investigated to determine if soybean immunotherapy can potentially provide benefit to peanut-allergic subjects. Although some protection was provided, additional experimentation with respect to optimal doses for sensitization and challenge will need to be investigated. In Model 4, the neonatal swine model was used to profile different foods (low to moderate to high sensitizing) similar to food allergies in humans. Evidence suggests such feasiblity; however, threshold levels for sensitization and allergic responses will need additional study. In summary, murine and swine animal models are being used to address immunotherapeutic avenues and investigation into the mechanisms of food-allergic sensitization.